NEA Management Company, LLC - REGULUS THERAPEUTICS INC ownership

REGULUS THERAPEUTICS INC's ticker is RGLS and the CUSIP is 75915K200. A total of 41 filers reported holding REGULUS THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
NEA Management Company, LLC ownership history of REGULUS THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$2,665,443
-6.8%
1,945,5790.0%0.21%
-5.5%
Q2 2023$2,860,001
+133.5%
1,945,579
+34.6%
0.22%
+156.5%
Q1 2023$1,224,734
-38.1%
1,445,1140.0%0.08%
-23.4%
Q4 2022$1,979,806
-19.4%
1,445,114
-0.0%
0.11%
-9.8%
Q3 2022$2,457,000
-17.9%
1,445,1150.0%0.12%
-20.1%
Q2 2022$2,991,000
-30.5%
1,445,115
-90.0%
0.15%
+24.2%
Q1 2022$4,306,000
+108.6%
14,451,147
+124.0%
0.12%
+195.2%
Q4 2021$2,064,000
-53.7%
6,451,0560.0%0.04%
-20.8%
Q3 2021$4,455,000
-14.7%
6,451,0560.0%0.05%
-22.1%
Q2 2021$5,225,000
-48.1%
6,451,0560.0%0.07%
-69.9%
Q1 2021$10,064,000
+15.6%
6,451,0560.0%0.23%
-1.7%
Q4 2020$8,709,000
+725.5%
6,451,056
+214.3%
0.23%
+411.1%
Q3 2020$1,055,000
-24.6%
2,052,4550.0%0.04%
-19.6%
Q2 2020$1,399,000
+47.9%
2,052,4550.0%0.06%
+14.3%
Q1 2020$946,000
-48.2%
2,052,4550.0%0.05%
-43.0%
Q4 2019$1,827,000
+23.6%
2,052,4550.0%0.09%
-29.5%
Q3 2019$1,478,000
-42.4%
2,052,4550.0%0.12%
-32.2%
Q2 2019$2,566,000
+174.7%
2,052,455
+124.1%
0.18%
+275.0%
Q1 2019$934,000
+9.6%
915,7510.0%0.05%
+41.2%
Q4 2018$852,000915,7510.03%
Other shareholders
REGULUS THERAPEUTICS INC shareholders Q4 2021
NameSharesValueWeighting ↓
Asymmetry Capital Management, L.P. 1,450,777$1,180,0000.81%
Endurant Capital Management LP 2,607,674$2,120,0000.58%
Sarissa Capital Management LP 1,851,851$1,506,0000.12%
Ikarian Capital, LLC 1,245,989$1,014,0000.08%
NEA Management Company, LLC 6,451,056$5,225,0000.07%
Focused Wealth Management, Inc 200,000$163,0000.03%
GSA CAPITAL PARTNERS LLP 206,265$168,0000.02%
GYL FINANCIAL SYNERGIES, LLC 41,000$33,0000.02%
Virtu Financial LLC 79,193$64,0000.01%
Pinz Capital Management, LP 22,300$18,0000.01%
View complete list of REGULUS THERAPEUTICS INC shareholders